TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01996059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y
Description: The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
Study: NCT00821002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Comparison of punctal plug placement between upper and lower puncta
Study: NCT04267445

Intervention type: PROCEDURE
Intervention: Embolization of prostatic artery under ultrasound guidance
Description: Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
Study: NCT01442987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Atorvastatin A
Description: once daily, P.O. 8week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: once daily, P.O. 8week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin A
Description: once daily, P.O. 8week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, P.O. 8week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Atorvastatin B
Description: once daily, P.O. 8week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin B
Description: once daily, P.O. 8week
Study: NCT03695445

Intervention type: DRUG
Intervention: Peripheral administration of Norepinephrine
Description: Systematic follow-up of complications from peripheral administration of Norepinephrine
Study: NCT03822026

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperventilation test
Description: Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
Study: NCT00543985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Echocardiography
Description: Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
Study: NCT03651206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP Inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Niraparib + TSR-042 (Dostarlimab)
Description: Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Drugs
Description: Chemotherapies given in standard of care
Study: NCT03711994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkantis
Description: cold therapy pack placed on the wound post operatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkantis
Description: cold therapy pack placed on the wound post operatively
Study: NCT01347060

Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate combination
Description: Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)

Intervention type: DRUG
Intervention: inhaled corticosteroids
Description: Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
Study: NCT02893891

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastric plication
Description: Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intragastric balloon
Description: The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intragastric balloon implantation
Description: Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
Study: NCT05358002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frontalis flap
Description: Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frontalis flap
Description: Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
Study: NCT03526211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES cycling
Description: On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
Study: NCT02996929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC System
Description: Subjects will undergo CIED lead extraction with the LC system
Study: NCT01349114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren 300 mg once daily
Description: aliskiren 300 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/sugar pill
Description: Sugar pill/placebo
Study: NCT04470765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zida
Description: Transcutaneous Tibial Nerve Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Zida
Description: Transcutaneous Tibial Nerve Stimulation
Study: NCT02152748

Intervention type: GENETIC
Intervention: analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
Study: NCT00125788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Study: NCT04196530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB001
Description: BDB001 is an immunotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB001
Description: BDB001 is an immunotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Study: NCT03187912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
Study: NCT02065596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant (HSCT)
Description: Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
Study: NCT02397694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: 75 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/25 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF
Description: 200/25 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily
Study: NCT00834704

Intervention type: DRUG
Group type: OTHER
Intervention: PEGPH20
Description: PEGylated recombinant human hyaluronidase
Study: NCT00424528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arformoterol Tartrate Inhalation Solution
Description: Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol and Tiotropium
Description: Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution and placebo inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution and placebo inhalation powder
Study: NCT01734980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound
Description: The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
Study: NCT03808038

Intervention type: OTHER
Intervention: None- Observational Study
Description: None- Observational Study

Intervention type: OTHER
Intervention: None- Observational Study
Description: None- Observational Study
Study: NCT01916473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion
Description: Continuous wound infusion via catheter
Study: NCT03067636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
Study: NCT03348748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03067636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management training A
Description: Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management training B
Description: Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
Study: NCT03348748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo lowest-dose of SBRT
Study: NCT02862886

Intervention type: OTHER
Group type: OTHER
Intervention: myometrium biopsy
Study: NCT03703115

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
Study: NCT00787384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
Study: NCT03348748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo lowest- or higher-dose of SBRT
Study: NCT01392443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
Study: NCT03348748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo highest-dose of SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgical Procedure
Description: Undergo thoracic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgical Procedure
Description: Undergo thoracic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgical Procedure
Description: Undergo thoracic surgery
Study: NCT04036149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Implantation as part of cataract surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens
Description: Implantation as part of cataract surgery
Study: NCT01578668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg given orally (po), daily (QD), starting on the first day of the first cycle
Study: NCT03554603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Report
Description: An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
Study: NCT00917995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypropylene Mesh, density 25-40g/square meter
Description: colostomy with a prophylactic hernia mesh
Study: NCT02782637

Intervention type: OTHER
Intervention: survey and interview
Description: all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences
Study: NCT01100541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric plate
Description: Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
Study: NCT00172809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 135 ug/week for 24 weeks
Study: NCT00648024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide Hydrochloride Capsules 1 mg
Description: 1mg, single dose fasting
Study: NCT00172809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alfa-2a
Description: Interferon alfa-2a 3 MU tiw for 24 weeks
Study: NCT00289133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Gamma Vacuum Foil polyethylene tibial insert

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: cross-linked polyethylene tibial insert
Study: NCT02644642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disconnection technique
Description: Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disconnection technique
Description: Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
Study: NCT00622817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylometazoline HCL 0.05%
Description: Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1mg
Description: Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
Study: NCT05988008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT03808038

Intervention type: OTHER
Intervention: None- Observational Study
Description: None- Observational Study
Study: NCT05988008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT02139995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBC transfusion based on different protocols
Description: transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion based on different protocols
Description: transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
Study: NCT00000255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Study: NCT04960631

Intervention type: DIAGNOSTIC_TEST
Intervention: Double site CT guided needle biopsy
Description: Double site CT guided needle biopsy
Study: NCT03109249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC1613
Description: Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference1613
Description: Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
Study: NCT03033485

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-P3BZA
Description: 18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
Study: NCT04253223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: REMD-477 will be administered as a subcutaneous injection for three weekly doses